AVANCES EN EL TRATAMIENTO DE LA LEUCEMIA MIELOIDE AGUDA (LAM)

The present report discusses advances in the treatment of acute myeloid leukemia (AML), which has improved markedly over the last 25 years. However, reality prevails, and the overall survival and disease-free survival in AML are still far from acceptable. There are three major reasons for this situa...

Full description

Saved in:
Bibliographic Details
Published inEl Farmacéutico hospitales no. 165; p. 5
Main Authors Bueno, J, Barrenetxea, C, E. Sánchez
Format Journal Article
LanguageEnglish
Published Barcelona Ediciones Mayo 01.05.2005
Subjects
Leukemia
Medical treatment
Mortality
Online AccessGet full text

Cover

More Information
Summary:The present report discusses advances in the treatment of acute myeloid leukemia (AML), which has improved markedly over the last 25 years. However, reality prevails, and the overall survival and disease-free survival in AML are still far from acceptable. There are three major reasons for this situation: the mortality associated with treatment, resistance to treatment and relapses (early or late). Thus, investigators continue to search for new approaches to the treatment of this disease. AML should be classified according to prognostic groups. This strategy enables the application of individualized treatment plans for the purpose of administering the most suitable therapy, addressing the causal factors as well.
ISSN:0214-4697